Literature DB >> 17483101

A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Thomas R E Barnes1, Carol Paton, Mary-Rose Cavanagh, Elizabeth Hancock, David M Taylor.   

Abstract

Reviews of the association between psychotic disorder, the metabolic syndrome, diabetes, and antipsychotic drugs conclude that there is a need for active, routine physical health screening of patients' prescribed antipsychotic drugs. From published guidelines, we derived the audit standard that all such patients should, as a minimum, have their blood pressure, body mass index (BMI) (or other measure of obesity such as waist circumference), blood glucose (or HbA(1c)), and plasma lipids measured at least once a year. We conducted an audit of the clinical records of 1966 eligible patients under the care of 48 multidisciplinary, assertive outreach clinical teams in 21 mental health services across the United Kingdom. This revealed a recorded measurement within the previous year for blood pressure in 26% of the patients, obesity in 17%, blood glucose (or HbA(1c)) in 28% and plasma lipids in 22%, with all 4 measures documented in 11%. In the total national sample, 6% had a documented diagnosis of diabetes, 6% hypertension, and 6% dyslipidemia. Extrapolating from the prevalence of these disorders in similar populations suggests that for every patient with a known diagnosis of diabetes, another had not been recognized, for every known case of hypertension, 4 had been missed, and for every known case of dyslipidemia, 7 had been missed. The responses of the clinical teams to a questionnaire yielded information on obstacles to screening in routine practice, revealing uncertainty about whose responsibility this was, a lack of confidence about the interpretation of abnormal screening results, and limited access to basic equipment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483101      PMCID: PMC2779874          DOI: 10.1093/schbul/sbm038

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  31 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

3.  Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study.

Authors:  Charles Motsinger; Michael Slack; Melanie Weaver; Morgan Reed
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

4.  Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs.

Authors:  David Taylor; Corina Young; Radia Mohamed; Carol Paton; Rebecca Walwyn
Journal:  J Psychopharmacol       Date:  2005-03       Impact factor: 4.153

Review 5.  Metabolic monitoring for patients treated with antipsychotic medications.

Authors:  Tony A Cohn; Michael J Sernyak
Journal:  Can J Psychiatry       Date:  2006-07       Impact factor: 4.356

Review 6.  Atypical antipsychotics and weight gain--a systematic review.

Authors:  D M Taylor; R McAskill
Journal:  Acta Psychiatr Scand       Date:  2000-06       Impact factor: 6.392

Review 7.  Antipsychotics and diabetes: review of non-prospective data.

Authors:  Peter M Haddad
Journal:  Br J Psychiatry Suppl       Date:  2004-04

8.  Smoking and malignancy in schizophrenia.

Authors:  E Masterson; B O'Shea
Journal:  Br J Psychiatry       Date:  1984-10       Impact factor: 9.319

Review 9.  Schizophrenia, the metabolic syndrome and diabetes.

Authors:  R I G Holt; R C Peveler; C D Byrne
Journal:  Diabet Med       Date:  2004-06       Impact factor: 4.359

Review 10.  Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement.

Authors:  Tim J R Lambert; Leon H Chapman
Journal:  Med J Aust       Date:  2004-11-15       Impact factor: 7.738

View more
  40 in total

1.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

2.  Physical Health and Dual Diagnosis.

Authors:  Debbie Robson; Sarah Keen; Pia Mauro
Journal:  Adv Dual Diagn       Date:  2008

Review 3.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

4.  [Detection of cardiovascular risk factors in patients with psychosis].

Authors:  Lydia Viñas; Maribel Fernández; Luisa San Emeterio; Luis M Martín-López
Journal:  Aten Primaria       Date:  2011-01-06       Impact factor: 1.137

Review 5.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  An expert panel assessment of comprehensive medication reviews for clients of community mental health teams.

Authors:  Natasa Gisev; J Simon Bell; Claire L O'Reilly; Alan Rosen; Timothy F Chen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-10-15       Impact factor: 4.328

7.  Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.

Authors:  Rebecca Ronsley; Kamini Raghuram; Jana Davidson; Constadina Panagiotopoulos
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-05

Review 8.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

9.  Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.

Authors:  David P J Osborn; Irwin Nazareth; Christine A Wright; Michael B King
Journal:  BMC Health Serv Res       Date:  2010-03-10       Impact factor: 2.655

10.  Standards of lithium monitoring in mental health Ttrusts in the UK.

Authors:  Noel Collins; Thomas Re Barnes; Amber Shingleton-Smith; David Gerrett; Carol Paton
Journal:  BMC Psychiatry       Date:  2010-10-12       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.